One afternoon in 2024, the BIO Federal Government Affairs team received a call from Hill staff who said, “We just met the most amazing […]
In Rare Trials Summit keynote, BIO expert highlights lives touched by PPRV Read More »
Continuing confusion about compliance is exacerbating the harms that new pharmaceutical tariffs cause the biotech industry, especially small innovative firms, experts say. Tariffs of
Tariffs’ drag on innovation compounded by lack of guidance, experts say Read More »
It’s been a long day at the university lab, but the researchers, who have been working on a niche bit of molecular biology research,
Bayh-Dole Act’s benefits include $3 trillion in U.S. output, report finds Read More »
The SBIR and STTR federal seed funding programs—essential to many biotech start-ups—have been updated with important changes that provide new opportunities to applicants. These
National Cancer Institute explainer for CSBA: Why and how to apply for SBIR Read More »
For decades, Congress has passed legislation to protect Americans from public health emergencies, ranging from national security threats to disease outbreaks and natural disasters,
A national security priority: BIO pushes PAHPA reauthorization in 2026 Read More »
With tariffs on patented pharmaceuticals and input materials set to take effect for all companies on Sept. 29, the lack of clarity about rules
With pharmaceutical tariffs looming, guidance on compliance is still lacking Read More »
A Food and Drug Administration (FDA) pilot program to expedite approval of new drugs contains potentially impactful initiatives but risks adding burdens, says the
BIO applauds efforts targeting early drug development efficiency, provides suggestions Read More »
An agreement designed to shape the future of drug approval recommends new efficiencies while leaning into the existing strengths of a system that makes
PDUFA letter stresses stability, transparency, maturity, says BIO negotiator Read More »
For people living with psoriatic disease, treatment innovation has advanced dramatically. Yet too many patients remain undiagnosed, untreated, or undertreated. The National Psoriasis Foundation
Connecting more patients with psoriasis to the care they need Read More »
BIO’s response to a request for information from the Drug Price Working Group explains why price setting won’t work. Improving patient access to new
Build patient access by strengthening innovation, BIO tells senators Read More »
